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Toll like receptorsInteractions between acute myeloid leukemia (AML) blasts and neighboring stromal cells are important for dis-
ease development and chemosensitivity. However, the molecular mechanisms involved in the cytokine-
mediated crosstalk between mesenchymal stem cells (MSCs) and AML cells are largely unknown. Leukemic
cells derived from 18 unselected AML patients were cultured with bonemarrowMSCs derived from healthy do-
nors; the populations then being separated by a semipermeable membrane. Coculture had only minor effects on
MSC proliferation. The unique cytokine network in cocultures was determined by high constitutive MSC release
of certain cytokines (especially IL-6 and vascular endothelial growth factor) and constitutive release of a wide
range of solublemediators by primary AML cells. However, the AML cell release varied considerably between pa-
tients, and these differences between patients were also reﬂected in the coculture levels even though supra-
additive effects were seen for many mediators. These effects on the local cytokine network were dependent on
a functional crosstalk between the two cell subsets. The crosstalk altered the global gene expression proﬁle of
the MSCs, especially expression of genes encoding proteins involved in downstream signaling from Toll like re-
ceptors, NFκB signaling and CCL/CXCL chemokine release. Thus, primary AML cells alter the functional phenotype
of normal MSCs.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acutemyeloid leukemia (AML) is a heterogeneousmalignancy char-
acterized by bone marrow inﬁltration of immature leukemia blasts
(Network, 2013; Welch et al., 2012; Reikvam et al., 2013a). The AML
cell population has a hierarchical organization including a minority of
leukemic stem cells (Bonnet & Dick, 1997) that often are included in
the CD34+/CD38− compartment (Bonnet & Dick, 1997). These cells
show self-renewal and long-term in vitro proliferation and have the ca-
pacity to produce leukemic progenitors showing proliferative but not
self-renewal capacity (Huntly & Gilliland, 2005). Both leukemic as
well as normal hematopoietic stem cells (HSCs) depend on support
from the bone marrowmicroenvironment (Lane et al., 2009). This sup-
port is at least partly mediated through the local cytokine network andaukeland University Hospital,
. Bruserud).
. This is an open access article underthe leukemic progenitors (i.e. the more mature leukemia cell subset) as
well as the stromal cells contribute to this network through their consti-
tutive cytokine release.
Mesenchymal stem cells (MSCs) can be isolated from various adult
tissues (includingbonemarrow), they aremultipotent and can differen-
tiate into cells of the mesodermal (e.g. adipocytes, osteocytes,
chondrocytes) as well as other embryonic lineages (Jiang et al., 2002).
MSCs can also be cultured in vitro and retain their multilineage poten-
tial (Pittenger et al., 1999). It is not known whether AML cells can
alter the biological functions of bone marrow MSCs. However, several
observations suggest that cells with a stromal phenotype are important
in leukemogenesis (Blau et al., 2011; Blau et al., 2007). MSCs may even
mediate resistance against antileukemic chemotherapy (Kojima et al.,
2011), possibly through their effects on the local cytokine network of
the bone marrow (Bruserud et al., 2007; Uccelli et al., 2008). Finally,
MSCs may also have immunomodulatory effects (Uccelli et al., 2008;
Le Blanc et al., 2007; Le Blanc et al., 2008), but it is not known whether
this is important for leukemogenesis or chemosensitivity. We havethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cells and differentiated stromal cells supports leukemia cell prolifera-
tion (Bruserud et al., 2004; Hatﬁeld et al., 2006), and in the present
study we investigated the cytokine-mediated crosstalk between prima-
ry human AML cells on immature MSCs.
2. Material and methods
2.1. AML patient population and preparation of primary AML cells
The study was approved by the local Ethics Committee (REK III,
University of Bergen, Norway) and samples collected after written in-
formed consent. Our department is responsible for the treatment of all
AML patients in a deﬁned geographic area, and the present study in-
cluded 18 consecutive and thereby unselected patients (10 males and
8 females; median age 67 years with range 18–87 years) with high
relative and/or absolute peripheral blood blast counts (N7 × 109/L)
(Supplementary Table 1). All patients were diagnosed according to the
WHO criteria (Döhner et al., 2010), and most of them had de novo dis-
ease. All AML cell sampleswere obtained fromperipheral blood, the leu-
kemic cells were isolated by density gradient separation (Lymphoprep,
Axis-Shield, Oslo, Norway) and gradient-separated cells contained at
least 95% leukemic blasts. Cells were stored in liquid nitrogen until
used in the experiments (Bruserud et al., 2003).
2.2. In vitro culture of mesenchymal stem cells and normal hematopoietic
cells
2.2.1. Normal human MSC
Human MSCs derived from the bone marrow of healthy Caucasian
donors (MSC24429, 45 years old male; MSC24539, 24 years old female;
MSC25200, 38 years old male) were purchased from Lonza (Cambrex
BioScience, Walkersville, MD, US). The cells showed no evidence for dif-
ferentiation towards the adipogenic, chondrogenic and ostogenic line-
ages, the donors had no evidence for HIV-1, hepatitis B or hepatitis C
infections, and all three cell preparations tested negative with regard
to mycoplasma, bacterial and fungal infections (distributor's in-
formation). The MSCs were expanded in complete Mesenchymal Stem
Cell Growth Medium (MSCGM™) (Lonza). Cells were obtained in pas-
sage two before being expanded, trypsinated and used for the experi-
ments in passage 3–4. Viability determined by trypan blue exclusion
was 50–80%..
2.2.2. Normal hematopoietic cells
Normal human hematopoietic progenitor cells (Lonza) were obtain-
ed by bone marrow aspiration from the posterior iliac crest of healthy
donors. The cells were cultured for ten days in Poietics™ primary
human hematopoietic progenitor growth medium that was supple-
mented with stem cell factor (SCF) 25 ng/mL, thrombopoietin (TPO)
50 ng/mL and FLT3-ligand (FLT3-L) 50 ng/mL. After culture 83.7% of
the nucleated cells were CD45+/117+/13+/10−/14−/HLA-DR+ blast-
like cells, 5.8% expressed lymphoid markers and 10.5% expressed neu-
trophil markers. The blast like population included 47% of cells showing
low CD34 expression whereas the remaining 53% were highly positive
for CD34.
2.2.3. Transwell cocultures
Coculture s of MSCs with normal or leukemic hematopoietic cells
were prepared in six well plates (Costar 3401 transwell plates; Costar,
Cambridge, MA, USA) where cells in the lower chamber are separated
from the cells in the upper chamber by a semipermeable membrane
(0.4 μm pore size). Cultures were prepared in complete MSCGM™me-
dium and MSCs were seeded in the lower chamber (6000 cells/cm2).
Pilot experiments showed that primary human AML cells cultured in
this medium showed cytokine-dependent proliferation that was com-
parable to the response in the StemSpan SFEM medium (Stem Cells,Vancouver, Canada) (data not shown). After four days, 1 × 106 normal
hematopoietic stem cells or primary human AML cells were added
to the upper well. Cells were cocultured for three additional days
before cells/supernatants were harvested or proliferation assayed
by 3H-thymidine incorporation as described in detail previously
(Bruserud et al., 2004; Hatﬁeld et al., 2006; Bruserud et al., 2003). The
mesenchymal cells did not reach conﬂuence during this culture.
2.2.4. Microtiter cultures of MSC
As described in detail previously (Bruserud et al., 2004; Hatﬁeld
et al., 2006) proliferation of MSCs was tested by 3H-thymidine incorpo-
ration in microtiter cultures.
2.2.5. AML cell culture supernatants
In accordance with previous studies the AML cells (1 × 106/ml,
2 ml/well, 24 well culture plates) were cultured in Stem Spanmedium
for 48 h before supernatants were harvested; at this time point the dif-
ferences between patients with regard to ability of AML cells to show
constitutive cytokine release are clearly seen (Bruserud et al., 2000).
2.3. Analyses of soluble mediator release
Supernatants were stored at−80 °C until analyzed. Cytokine levels
determined by Luminex analyses (R&D Systems, Abingdon, UK) includ-
ed (i) the growth factors tumor necrosis factor α (TNFα), basic
ﬁbroblast growth factor (bFGF), hepatocyte growth factor (HGF), hepa-
rin binding-epidermal growth factor (HB-EGF), granulocyte colony-
stimulating factor (G-CSF) and granulocyte-macrophage colony-
stimulating factor (GM-CSF); (ii) the interleukins (IL) IL1-RA, IL-1β, IL-
6, IL-10 and IL-33; (iii) the chemokines CCL2-5, CXCL1/5/8/10/11; and
(iv) matrix metalloproteases 1 (MMP-1) and 2 (MMP-2). IL-8/CXCL8,
MMP-9, tissue inhibitor of MMP1 (TIMP-1) and angiopoietin-1 (Ang-
1) levels were analyzed by enzyme-linked immunosorbent assays
(ELISAs) (R&D Systems). All analyses were performed strictly according
to the manufacturer's instructions.
2.4. Analysis of intracellular mediator levels
MSCs were trypsinized and the cell pellets (after centrifugation at
600 ×g for ﬁve minutes) were resuspended in Shieh lysis buffer. After
30 min of incubation on ice, the suspension was centrifuged at
13.000 ×g for 30 min. The clear lysate was harvested and stored at
−80 °C until the levels of (1) p65 (RelA) that is the association partner
of themature subunit of NFκB, (2) the p65 inhibitor IκB, and (3) the p65
activator, IKKα/β were determined by Luminex analyses (Merck
Millipore, Darmstadt, Germany).
2.5. RNA preparation, microarray analysis of global gene expression and
PCR analyses
The MSCs from the lower wells were lysed in RLT plus buffer with
added β-mercaptoethanol according to QIAgen's RNeasy protocol and
thereafter homogenized by the aid of QIAshredder columns according
to themanufacturer's recommendations. The lysateswere stored frozen
at−80 °C until thawing at 37 °C in a water bath and handled according
to QIAgen's instructions in the RNeasy with DNase treatment protocol
for the QIAcube. All microarray assays were performed using the
Illumina iScan Reader and based on ﬂuorescence detection of biotin-
labeled cRNA. For each sample 300 ng total RNA was reversely tran-
scribed, ampliﬁed and Biotin-16-UTP-labeled using the Illumina
TotalPrep RNA Ampliﬁcation Kit (Applied Biosystems/Ambion; Foster
City, CA, USA). Amount and quality of the biotin-labeled cRNAwere con-
trolled both by the NanoDrop spectrophotometer and Agilent 2100
Bioanalyzer before 750 ng of biotin-labeled cRNA was hybridized to
the HumanHT-12 v4 Expression BeadChip according to manufacturer's
Table 1
The levels (pg/mL) of soluble mediators in supernatants derived from cultures containing
primary AML cells alone (18 patients examined), MSC24539 alone and cocultures of MSC
and AML cells.
Mediator MSC alone AML alone MSC + AML coculture
Chemokines
CCL2 2351 2362 (19.8–3902) 4713 (2371–6253)
CCL3a nd 1067 (34–41518) 2092 (86–42167)
CCL4a 17.5 487 (4.9–9377) 1254 (42–17629)
CCL5a 26 226 (9–55553) 10578 (29.7–55553)
CXCL1a 20 1049 (nd–9830) 13705 (120–13044)
CXCL5a 263 376 (nd–55553) 10427 (297–55553)
CXCL8a 307 31105 (257–115815) 49342 (768–379791)
CXCL10a 1.1 42 (1.3–542) 3.6 (1.1–889)
The interleukin system
IL-1β 0.1 9.6 (1.1–133) 68 (nd–1622)
IL-1RAa 0.8 9867 (17–N14441) N14441 (20–N14441)
IL-6 1488 220 (0.5–N2775) 2775 (705–N2775)
IL-10 nd 0.7 (nd–60.0) 3.8 (nd–245)
Growth factors
TNFα 1.3 9.4 (nd–1487) 10.6 (2.1–1489)
HGF 152 17.7 (3.1–266) 92 (27.6–641)
VEGF 1147 7.4 (0.9–108) 1163 (1147–1254)
bFGFa 5.4 nd (nd–4.3) 14.6 (8.5–24.5)
G-CSFa nd nd (nd–357) 263 (nd–4049)
GM-CSFa 1.2 2.8 (0.4–834) 118 (1.6–2207)
The MMP system
MMP-1a 700 152 (nd–14263) 3987 (303–14263)
MMP-2 20367 6888 (854–12918) 23357 (18594–22826)
MMP-9a 329 13718 (235–215189) 23032 (279–227465)
TIMP-1 121752 5956 (nd–37990) 105858 (61019–145948)
The concentrations of the MSCs alone are presented as the mean of duplicate determina-
tions, the variation between duplicates being generally b10% of the mean. The AML and
coculture results are presented as themedian and the variation range, respectively. Abbre-
viation: nd, not detected.
a Means at least 9 patients showing supra-additive levels.
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genes in the NCBI RefSeq database (Release 38).
Real-time PCR was carried out in triplicate on an ABI Prism 7900HT
sequence detector system (Applied Biosystems) using cDNA synthe-
sized by means of a High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) as template. Primers were designed using Primer
(Rozen & Skaletsky, 2000). RT-PCR relative gene expression levels were
determined using the comparative ΔCt method, using β-actin (Actb)
and ribosomal protein, large, (Rplp0) as endogenous controls.
2.6. Statistical and bioinformatical analyses and presentation of the data
All statistical analyses were performed using the Statistical Package
for the Social Sciences (SPSS) version 21.0 (SPSS Inc., Chicago, IL, USA)
and GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA, USA),
and p-values b0.05 were regarded as statistically signiﬁcant. The data
from the scanning of arrays (IlluminaiScan Reader) were examined in
GenomeStudio and J-Express 2012 (MolMine AS, Bergen, Norway) for
quality control (Stavrum et al., 2008). All arrays were quantile normal-
ized before being compiled into an expression proﬁle data matrix.
Genes were collapsed using the max probe for merge statistics, before
analysis. Gene ontology (GO) terms were identiﬁed using the Gene On-
tology website (http://www.geneontology.org/GO.current.annotations.
shtm). Other bioinformatical analyses were performed using the
J-Express 2012 analysis suite (MolMine AS) (Stavrum et al., 2008).
3. Results
3.1. Coculture of MSCs with primary AML cells has no or only minor effects
on MSC proliferation
We compared MSC proliferation (MSC24429, MSC24539,
MSC25200) for transwell cocultures with primary AML cells (Supple-
mentary Table 1) and AML-free control cultures; proliferation was
then assayed as 3H-thymidine incorporation. We seeded 20,000 MSCs
in the lower chamber of each transwell, and the cells were harvested
when the cells showed ≤70% conﬂuence. No difference in MSC viability
was observed by microscopic examination during culture. The three
MSCs showed a similar and relativelyweak proliferation in repeated ex-
periments (range 2706–6072 cpm); 3H-thymidine incorporation
b1000 cpm was regarded as no detectable proliferation whereas
cytokine-dependent AML cell proliferation (50,000 cells per well)
often corresponds to 20, 000–50,000 cpm (Bruserud et al., 2003).
When using this assay for other cell types we have deﬁned a signiﬁcant
difference in the proliferation to correspond to 2000 cpm (Bruserud
et al., 2003); a difference N2000 cpm for at least two of the MSCs was
only seen for three patients (always increased proliferation). A twofold
alteration was not observed for any patient for MSC24429 and
MSC25200, whereas this was seen for seven patients when testing
MSC24539 (Supplementary Fig. 1). Thus, when using a 3H-thymidine
incorporation assay all three MSCs showed relatively low proliferation
and coculture with primary AML cells caused either no signiﬁcant alter-
ation or only a minor increase in MSC proliferation.
3.2. Different MSC populations show similar cytokine release proﬁles
MSC24429, MSC24539 and MSC25200 were cultured in medium
alone and the MSCs then showed similar cytokine release proﬁles
with (Tables 1 and 2 for MSC24429 and MSC24539): (i) undetectable
(only CCL3) or relatively low absolute levels (b100 pg/mL) of CCL4–5,
CXCL10, IL-1β/1RA/10, TNFα, bFGF, G-CSF and GM-CSF; (ii) 100–
500 pg/mL of CXCL5 and HGF; (iii) 500–5000 pg/mL of CCL2, IL-6,
VEGF and MMP-1; and (iv) N5000 pg/mL of MMP-2 and TIMP-1. A lim-
ited variation between MSCs corresponding to less than ﬁvefold varia-
tions and/or an absolute difference less than 200 pg/mL was seen for
CXCL1, CXCL8 and CXCL11. Only MMP-9 (range 4.8–329 pg/mL)showed a relatively wide variation between the threeMSCs. This medi-
ator release proﬁle was reproduced in independent experiments and is
consistent with previous studies (Kastrinaki et al., 2013; Kemp et al.,
2005; Ranganath et al., 2012).
3.3. Supra-additive cytokine levels can be seen in MSC-AML cell cocultures
MSC24429, MSC24539 and MSC25200 were cocultured in transwell
cultureswith primary humanAML cells derived fromall 18 patients and
levels of solublemediators determined in the supernatants. Control cul-
tures were prepared with AML cells andMSCs alone. The overall results
for MSC24539 are summarized in Table 1, and the results for MSC24429
are summarized in Fig. 1. MSCs cultured alone showed relatively high
levels (i.e. levels comparable or higher than the corresponding median
level for AML cells alone; for absolute levels see Table 1) of CCL2, IL-6,
HGF, VEGF, MMP-1, MMP-2 and TIMP-1. The AML–MSC coculture levels
of thesemediators were also relatively high. In addition, bFGF showed a
similar pattern with relatively high levels for MSCs compared with the
AML cells (i.e. MSC release higher than the median AML release); al-
though both cell types showed relatively low absolute levels compared
with several other cytokines. For all these mediators the variations be-
tween patients were relatively small both for CCL2 (b4.0 fold variation),
VEGF (3.4 fold), bFGF, (4.3 fold)MMP-2 (1.2 fold) and TIMP-1 (2.4 fold).
Even the variation for HGF (23.2 fold) is much lower than for many of
the mediators constitutively released only by AML cells. Similar results
were observed for the two other MSCs cocultures (data not shown). Fi-
nally, the clustering shown in Fig. 1B does not show any association
with differentiation (FAB classiﬁcation, CD34+ expression) or genetic
abnormalities.
Supra-additive levels were often detected in the cocultures (i.e. co-
culture levels higher than the summarized levels for MSCs and AML
cells cultured alone): (i) at least nine out of the 18 patients showed
Table 2
Supernatant level (pg/mL) of various mediators after in vitro culture of MSC24539 alone,
HSCs alone and transwell cocultures of MSCs + HSCs. Supra-additive levels in the cocul-
tures are given in bold.
MSC alone HSC alone MSC + HSC
Chemokines
CCL2 822.2 224.2 1662
CCL3 23.8 39.8 29.0
CCL4 66.9 57.7 101
CCL5 0.98 37.2 27.2
CXCL1 210 207 376
CXCL5 141 99.2 416
CXCL8 647 312 1352
CXCL10 2.4 2.3 2.7
CXCL11 172 131 196
Interleukins
IL-1β 6.8 5.1 13.4
IL-1RA 7.8 86.4 906
IL-6 630 45.0 468
IL-10 26.8 24.4 14.7
Growth factors
TNFα 6.6 3.0 9.1
HGF 124 16.4 325
bFGF 81.0 64.9 74.3
Ang-1 767 710 1225
G-CSF 50.4 34.8 42.5
GM-CSF 17.7 19.5 18.4
MMP/TIMP
MMP-1 3502 87.7 6716
MMP-2 17,691 3736 19,076
MMP-9 4.8 5.9 13.8
TIMP-1 58,600 5800 56,800
All concentrations are given in pg/mL. All analyses were performed in duplicates and the
difference between the two measurements generally corresponded to b10% of the
mean. The MSC alone results are the mean level for 4 independent cultures, the HSC and
coculture results represent the mean of two independent cultures each.
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were coculturedwith all threeMSCs; and (ii) supra-additive levels for at
least half of the patients with two out of the three MSCs were observed
for CCL3/4/5, CXCL10, IL-6, IL-10, bFGF, G-CSF, GM-CSF and MMP-1
(data not shown). Thus, supra-additive levels in cocultures were un-
common only for eight of the 24 mediators tested; these exceptional
mediators included IL-1β, TNFα and CXCL11 that showed low release
for most cultures and the ﬁve mediators that showed relatively high re-
lease byMSCs cultured alone (CCL2, HGF, VEGF,MMP-2 and TIMP-1; see
above) (data not shown).
To further illustrate the observation of supra-additive effects we did
a cluster analysis (Fig. 1). For each mediator and patient we estimated
the relative increase, i.e. (the level in cocultures minus the correspond-
ing level for MSCs cultured alone): (the corresponding level for AML
cells cultured alone). Hence, a ratio N1 indicates a supra-additive level.
These valueswere log(2) transformed before used in a hierarchical clus-
tering analysis, a value N0 then indicates a supra-additive effect. The
mediators then formed two main clusters: one subset consisted of me-
diators showing minor alteration in cocultures and included several
chemokines (CCL3-5, CXCL10/11 together with TNF-α, MMP-9, bFGF,
HB-EGF, IL-1RA/β/10 and GM-CSF. The other subset consisted of the
mediators showing strong supra-additive effects in cocultures (ratio
being N1.0) and included CCL2, CXCL1/5/8, TIMP-1, IL-6, G-SCF, HGF,
and Ang-1. The detection of supra-additive levels is summarized in
the Supplementary Fig. 2; the ﬁgure shows the levels for those 15 cyto-
kines that showed supra-additive levels for at least 9 patients and for at
least 2MSCs. Supra-additive levelswere common andwere detected for
most patients and with all three MSCs, they were also seen for the four
exceptional patients identiﬁed as described in section 3.7 (patients 4, 6,
12, 14) and detection of supra-additive levels showed no signiﬁcantassociation with AML cell differentiation or genetic abnormalities (see
Supplementary Table 1).
3.4. Individual differences between patients in constitutive AML cell release
of soluble mediators are also reﬂected in the coculture levels
There was a wide variation among patients in the release of several
mediators, and we therefore investigated whether there was any corre-
lation between coculture levels and the corresponding levels for AML
cells cultured alone. The results for CCL3, IL-1RA and MMP-9 are
presented in Fig. 2; these results illustrate those signiﬁcant correlations
between AML culture and coculture levels could be detected for differ-
ent mediators even when they showed supra-additive effects in cocul-
tures. Signiﬁcant correlations (p ≤ 0.004 unless otherwise stated)
between AML and coculture levels were also observed for CCL4, CCL5
(only MSC24429), CXCL1 (p = 0.023 for MSC25200), CXCL5, CXCL8,
CXCL10 (p = 0.008 for MSC24539), IL-1β, TNFα, HGF (p = 0.0023 for
MSC24429), bFGF (p = 0.012 for MSC24539), GM-CSF, G-CSF (only
for MSC24429) and MMP-9 (data not shown). Thus, a majority of the
17 soluble mediators showing undetectable or relatively low constitu-
tive release by normal MSCs compared with the AML cell (i.e. the MSC
release being lower than the median AML cell release) shows a wide
variation between patients with regard to constitutive primary AML
cell release, and this patient-dependent variation is maintained in
AML–MSC cocultures. Despite this heterogeneity with regard to clinical
and biological characteristics (Supplementary Table 1) among our con-
secutive patients (including differences in the constitutive cytokine re-
lease), a majority of our patients showed a similar qualitative (i.e.
supra-additive) but not quantitative modulation of the local cytokine
network during coculture.
3.5. The altered cytokine network in AML–MSC cocultures depends on a
crosstalk between the cells
Wecompared the local cytokine network for (i) AML–MSC24539 co-
cultures; and (ii)MSCs alone culturedwith 50% of themediumbeing re-
placed with 50% AML cell supernatant derived from ﬁve patients
showing high constitutive cytokine release. The mediator levels were
higher in the corresponding cocultures for all ﬁve patients for (i) the
chemokines CCL2/4, CXCL5/10; (ii) IL-1β/6/10; (iii) the growth factors
G-CSF, GM-CSF; and (iv) MMP-1/9. Furthermore, we cultured
MSC24429 and MSC25200 in the presence of exogenous single cyto-
kines (CCL2-4, CXCL1, CXCL8, IL-6), dual combinations (IL-6 + CXCL1,
IL-6 + CXCL8, CXCL8 plus each of CCL2-4) or triple combinations
(CXCL8 + IL-6 plus each of CCL2-4) (data not shown). The levels of 24
soluble mediators were determined in the supernatants; even though
the effects differed betweenmediators/combinations, theywere always
similar for bothMSC donors: (i) a general decrease for at least 12 of the
14 cultures was seen for CCL2, CXCL1, IL-6, HGF, MMP-1; and (ii) TNFα
levels increased 5–10 fold for cultures containing CCL2, and CXCL5
levels increased approximately 2–3 fold for cultures containing CXCL8
(data not shown). Thus, single cytokines, cytokine combinations and
AML supernatants could alter the constitutive MSC cytokine release,
but such effects could not explain themore extensive or different effects
seen in the cocultures. Themore extensive effects can only be explained
by an active crosstalk between AML cells and MSCs.
3.6. The cytokine network during coculture of MSC and normal
hematopoietic cells
We compared the cytokine release for MSC24429 cultured alone,
normal hematopoietic cells cultured alone (one donor, two indepen-
dent experiments) and cocultures of MSC24429 with normal hemato-
poietic cells (Table 2). Supra-additive effects were seen for several
mediators. Thus, there is also a crosstalk via the soluble mediator net-
work betweenMSCs and normal hematopoietic cells, but the ﬁnal effect
Fig. 1. The effect of the cytokine-mediated crosstalk between primary humanAML cells andMSCs on the local cytokine network.MSC24429 derived from a healthy donorwere cocultured
in transwell cultures togetherwith primary AML cells derived from 18 patients. We determined the cytokine levels in supernatants harvested from AML–MSC cocultures and correspond-
ing control cultures only containing AML cells orMSCs. (A) The fold changewas deﬁned as the level in coculture relative to the corresponding level for AML cells cultured alone. The ﬁgure
presents themedian fold change for all 18patients and for each solublemediator. (B)We also performed a hierarchical clustering analysis based on the ratio of cytokine levels inAML–MSC
cocultures and AML cell cultures. Each horizontal row in the ﬁgure represents the observation for one patient, and a vertical column represents the observations for one of the soluble
mediators. Red indicates increased fold change,white nodifference and green decreased fold change. Twomajor cytokine subsets were identiﬁed; the leftmain cluster includedmediators
usually showing no or only minor alterations in AML–MSC cocultures, whereas the right main cluster included mediators that are usually showing increased fold change in cocultures.
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and leukemic cells. For the normal cells supra-additive levels were seen
for fewer (7 versus 15) and partly other mediators (CCL2, IL-1β, HGF)
than for the AML cells, the common mediators with supra-additive ef-
fects being CXCL5, IL-1RA and MMP-1/9).
3.7. AML cells alter the global gene expression proﬁle of MSCs whereas nor-
mal hematopoietic stem cells have only minor effects
We examined the global gene expression proﬁle for MSC24429 cul-
tured alone (four parallel cultures), together with normal hematopoi-
etic cells (two parallel cultures) and together with primary humanAML cells derived from all 18 patients (Supplementary Table 1). First
we investigated the co-variance between samples and performed a
correspondence analysis that allowed the display of low-dimensional
projection of the data and identiﬁcation of samples with similar behav-
ior (Fig. 3) (Fellenberg et al., 2001). The X-component variance distin-
guished the majority of patient samples both from the four cultures
containing MSC alone and the two cultures containing MSC with nor-
mal hematopoietic cells, whereas the patients were heterogeneous
and AML cells derived from four exceptional patients localized relative-
ly close to the control samples compared with the other 14 patients.
Despite the Y-component variation between the 4 MSC controls, it
can be seen that the majority of the 14 AML patients localized away
Fig. 2. Supernatant concentrations of IL-1RA (A, D, G), CCL3 (B, E, H) and MMP-9 (C, F, I) in cocultures of MSCs and primary human AML cells. MSC24539 (A, B, C) and MSC25200 (D, E,
F) and MSC24429 (G, H, I) were cultured in transwell cultures together with primary human AML cells derived from 18 unselected patients. For a large majority of patients IL-1RA, CCL3
and MMP-9 showed supra-additive levels in cocultures compared with control cultures including MSCs or AML cells alone. We compared the mediator concentrations for cultures con-
taining AML cells alone and the corresponding AML–MSC cocultures, and for each ﬁgure we show the results from this correlation analysis (p-value, r-value).
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tional patients.
We used the signiﬁcance analysis ofmicroarrays (SAM) algorithm to
circumvent the problems of multiple testing (Tusher et al., 2001) and
compared the global MSC gene expression proﬁle for cells cultured
alone and together with AML cells. An algorithm of 400 permutations
was used. When comparing the most differently expressed genes with
a false discovery rate (FDR) b1.0, we identiﬁed 89 genes that showed
a highly different expression in MSCs cultured with AML cells (45 up-
regulated and 44 down-regulated). These 89 genes were then used for
hierarchical clustering analysis (Pearson's correlation with complete
linkage) (Fig. 3); one cluster then included MSCs cocultured with 14
of the AML samples whereas the other main cluster included the MSCs
cultured in medium alone, together with normal hematopoietic cells
and together with the four exceptional AML samples. Furthermore,
within this last main cluster the four MSC samples, the two normal he-
matopoietic cell samples and the four exceptional patients formed sep-
arate subclusters.
The AML cells derived from the four exceptional patients (see Figs. 3
and 4) were heterogeneous with regard to predisposition (2 secondary
AML and 2 de novo), morphological signs of differentiation (FAB classi-
ﬁcation), CD34 expression and genetic abnormalities (Supplementary
Table 1).We also performed a hierarchical clustering of all AML patients
based on the constitutive cytokine release by AML cells cultured alone.
The 18 patients could be divided into twomain clusters and several sub-
clusters based on their cytokine release proﬁles, but the four exceptional
patients then clustered separately, i.e. they did not form a common clus-
ter due to a similar and speciﬁc constitutive cytokine release proﬁle(Supplementary Fig. 3). We ﬁnally identiﬁed those genes (i) included
in the clustering analysis presented in Fig. 3 and (ii) showing a different
expression for the majority of 14 patients compared with the 4 excep-
tional patients, i.e. all patients in one group showing increased and all
patients in the other group showing decreased expression. The 13 iden-
tiﬁed genes are presented in Supplementary Table 2: six of the 11 genes
with a known function are known to be important for NFκB signaling/
function and two additional genes possibly have a role in transcriptional
regulation. Our data have to be interpretedwith care because the excep-
tional patients are few, but taken together our observations suggest that
these exceptional AML patients differ from themajority of patients with
regard to the regulation and/or role of NFκB in the MSCs whereas their
common effect on MSC gene expression is not induced by a common
and speciﬁc cytokine release proﬁle.
The expression of selected genes showing altered expression inMSC
cocultured with primary human AML cells (CCL2, CXCL6, IL8, IRAK2,
NFKB1A)were validated by PCR analyses, and for all these genes a strong
correlation was observed between the microarray and the PCR data
(Supplementary Fig. 4; r ≥ 0.068 and p ≤ 0.003 for ﬁve genes).
3.8. Gene set enrichment analysis detected upregulation of distinct MSC
functions after coculture
Gene set enrichment analysis (GSEA) was used to identify gene on-
tology (GO) terms associated with coculture-induced differences in the
gene expression proﬁle of MSC24429 (all 18 patients included in the
analysis) (Subramanian et al., 2005). Several GO-terms were highly
enriched in MSCs cocultured with AML cells from the 18 patients, and
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terms could then be further classiﬁed (AmiGo) into 12 main groups
based on their biological function (Fig. 4 and Supplementary Table 3).
These GO-terms included terms important for gene transcription
(nucleotide binding, nucleic acid metabolism, NFκB), protein synthesis
and stabilization (ribosome activity, heat shock protein/unfolded
protein response), regulation of leukocyte functions/metabolism
(leukocyte activation, interleukin activation, metabolism, chemokine
activity, response to lipopolysacharide/bacteria, VEGF activity) and in-
tracellular signaling (Toll-like receptor signaling pathway, NFκB).
Thus, several of these terms describe interacting steps in the same sig-
naling pathway: initial response to lipopolysaccharide/bacteria through
ligation of Toll like receptors followed by downstream signaling involv-
ing NFκB that can translocate to the nucleus initiate expression of
chemokines/interleukin through nucleotide binding.
When using the leading edge genes derived from these 41GO-terms
we identiﬁed 275 genes that belonged to at least oneGO-term andwere
upregulated in coculturedMSCs. These 275 genes were used to perform
a hierarchical clustering analysis and we then identiﬁed the samemain
clusters aswith the SAM analysis (Fig. 4); onemain cluster included the
same 14 patients andwithin the othermain cluster the fourMSCs alone,
the two normal hematopoietic and the same four exceptional patient
samples formed three separate subclusters.
3.9. AML cells increased theMSC expression of genes involved in TLR initiat-
ed and NFκB mediated intracellular signaling together with increased CCL
and CXCL chemokine expression
Using a Feature Subset Selection we were able to identify individual
genes with highly increased expression in MSCs after coculture with
primary AML cells. The 15 genes with the highest fold change then in-
cluded genes encoding extracellular mediators (Bruserud et al., 2007;
Reikvam et al., 2013b), i.e. seven chemokines (CCL2, CCL20, CXCL1/2/
5/6/8) together with IL-1β, IL-6 and MMP-3. The expression of several
of these mediators is regulated by TLR initiated and/or NFκB mediated
intracellular signaling (Bruserud et al., 2007; Zeytun et al., 2010).
Thus, both this last analysis as well as the identiﬁcation of signiﬁcantly
altered GO-terms showed that the AML–MSC cytokine crosstalk modu-
lates the TLR/NFκB/chemokine axis in normal MSCs. We therefore ana-
lyzed more in detail the three GO-terms TLR, NFκB and chemokine
activity (Fig. 5). Several highly upregulated genes were included both
in the TLR and NFκB terms; among the highest upregulated common
genes were NFKBIA, IRAK2, IRAK3, NKB1 and IKBKE. Furthermore, the in-
creased mRNA expression of CCL2, CCL20, CXCL1, CXCL2, CXCL6, IL8, IL1B
and IL6 all corresponded to a more than 3.8 fold change, being highest
for IL8 (65.5), CXCL1 (28.6), CXCL6 (27.0) and IL6 (18.6) (Fig. 5).
MSCs are able to differentiate in various directions including adipo-
cytes and osteoblasts. The GO term Adipocyte differentiation includes
19 genes (AACS, ADRB1, ADRB2, ALDH6A, ARL4A, CBY1, CCND1, CTBP1,
DNAJA4, FABP4, FGF10, PPARG, PSMB8, RARRES2, RGS2, SDF4, SIRT1,
TBLY1, TRIM32) and the term Osteoblastic differentiation includes 13
genes (DHX9, DNAJC13, EPHA2, ERH, GLI2, IGFBP5, PTH1R, PTHLH,
RUNX2, SATB2, SMAD3, SPP1, TWIST2). None of these 32 genes were
among themost deregulated genes identiﬁed in any of the analyses de-
scribed above. We then compared their expression for MSCs cultured
alone and MSCs cocultured with the 18 primary AML cells. All theseFig. 3. Modulation of the MSC global gene expression proﬁle caused by the cytokine-med
(A) Correspondence analysis; mesenchymal stem cells (MSC24429) derived from a healthy do
together with normal hematopoietic cells in two cultures (green squares) and together with
gene expression proﬁle of the MSCs was determined for all these cultures. The correspondence
tweenMSCpopulationswith differences in their global gene expression proﬁle, i.e.MSCs culture
majority of theMSC–AML cocultures (14 out of the 18 patients). (B)We also performed a signi
identiﬁed 89 differentially expressed geneswith a false discovery rate (FDR) b1.0. The results ar
in cocultured MSCs and 44 were downregulated. The 89 genes could be used for a hierarchica
guished between MSCs cultured alone (blue bars), MSCs coculture with normal hematopoietic
AML patients could be identiﬁed in this analysis as in the correspondence analysis (A).genes showed generally low expression with no signiﬁcant difference
between MSCs cultured alone and together with leukemic cells, the
only exception being the osteoblast-associated IGFB1 that showed de-
creased expression in the presence of leukemic cells. IGFBP5 is secreted
by preosteoblasts but decreases during their differentiation (Mukherjee
& Rotwein, 2007). However, the IGF system is a growth regulator for
many differentiated cells, and altered expression of this marker alone
cannot be regarded as a sign of differentiation. The expression of these
32 differentiationmarkers did not differ between themajority of 14 pa-
tients and the 4 exceptional patients identiﬁed in Figs. 3 and 4 either.
3.10. MSCs cocultured with primary AML cells show altered NFκB signaling
MSC25200 cells were cocultured in transwell cultures with primary
AML cells derived from the 18 patients before MSC lysates were pre-
pared. The levels of the two stimulatory mediators p65/RelA and IKK
and the inhibitory mediator IKBα/βwere determined and the stimula-
tor versus inhibitor ratios p65/IKB and IKK/IKBαβ estimated (Fig. 5).
An increase of both ratios (i.e. increased stimulatory activity) was de-
tected for 11 patients, additional 4 patients had one increased ratio
and the last 3 patients showed no increase for any ratio. These 3 last pa-
tients included one of the exceptional patients from the global gene ex-
pression studies (Supplementary Table 1, patient 12) and two patients
(patients 13 and 16) included in the major subset identiﬁed in Fig. 3.
Thus, our results from these protein studies in cocultured MSCs also
suggest that NFκB signaling is altered in the stromal cells after coculture
with primary human AML cells.
4. Discussion
AML is a heterogeneousmalignancywith regard to the biology of the
leukemic cells, and bone marrow stromal cells support the growth of
primary human AML cells (Bruserud et al., 2004; Hatﬁeld et al., 2006;
Reikvam et al., 2013b; Reikvam et al., 2012). In the present studywe fo-
cused on the cytokine-mediated crosstalk between AML cells and MSCs
and how this communication alters the biological characteristics of nor-
mal MSCs.
Our MSCs were derived from three healthy individuals and showed
several common characteristics; only one of themwas therefore includ-
ed in the global gene expression studies. Firstly, theMSCs expressed cell
surface molecules consistent with a normal MSC phenotype (Kemp
et al., 2005; Lv et al., 2014). Secondly, our MSCs showed only minor dif-
ferences in their constitutive cytokine release proﬁles and several of
these cytokines are constitutively released by normal MSCs during
in vitro culture (Kastrinaki et al., 2013; Kemp et al., 2005; Ranganath
et al., 2012). Thirdly, the presence of primary AML cells had no or only
weak effects onMSC proliferation. Finally, all three MSC populations in-
creased the in vitro proliferation and viability of primary human AML
cells during coculture (Ito et al., 2014). Thus, our MSCs usually showed
similar functional characteristics in various experimental models with
only minor differences; these minor differences between our MSC pop-
ulations are thus not caused by age-dependent differences (Liedtke
et al., 2015; Lepperdinger, 2011). Taken together our observations sug-
gest that themicroarray data for theMSC24429 cells should be regarded
as representative for our three normal human MSC populations. How-
ever, our results should be interpreted with care because of the limitediated crosstalk between primary human AML cells and MSCs in transwell cocultures.
nor were either cultured alone in four independent cultures (blue squares in the ﬁgure),
primary human AML cells derived from 18 unselected patients (red squares). The global
analysis of the 24 proﬁles showed that the X-component could be used to distinguish be-
d alone,MSCs cultured togetherwith normal hematopoietic cells andMSCs derived from a
ﬁcance analysis of microarrays (SAM) of theMSC global gene expression proﬁles. We then
e presented as a heatmap togetherwith clustering denograms; 45 geneswere upregulated
l clustering analysis (Pearson correlation with complete linkage), and this analysis distin-
cells (green bars) and MSCs cocultured with AML cells (red bars). The same 4 exceptional
Fig. 4. Cytokine-mediatedmodulation of theMSC global gene expression proﬁle during coculture (transwell cultures)with primary humanAML cells— a gene set enrichment analysis (GSEA). The analysiswas performed by comparing the proﬁles for
MSC24429 cultured alone, coculturedwith normal hematopoietic cells and coculturedwith primary human AML cells (18 patients included). By using GO-termswith false discovery rates b0.01we identiﬁed 41 GO-terms that could be classiﬁed into
12 main groups (Supplementary Table 2), and we then identiﬁed 275 genes belonging to the leading edge of at least one of these 41 GO-term. Finally these 275 genes were used to perform a hierarchical clustering analysis (Pearson correlation,
complete linkage), and based on this analysis we could distinguish between MSCs cultured alone (right margin, blue color), MSCs cocultured with normal hematopoietic cells (green color) and MSCs cocultured with AML cells (red color). The
same four exceptional patients were identiﬁed as in the previous analyses (Fig. 3). In the lower part of the ﬁgures the leading edge genes for each of the 12 major subgroups are identiﬁed (lower right part).
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induced differences in MSCs will inﬂuence the effects of the cocultures.
Our in vitro model was based on the use of transwell cultures
(Bruserud et al., 2004; Hatﬁeld et al., 2006; Glenjen et al., 2002;
Hatﬁeld et al., 2009), and we could thereby investigate the cytokine-
mediated crosstalk between MSCs and primary AML cells without the
inﬂuence of direct cell–cell contact. We used a growth-factor supple-
mented culture medium that has been developed for MSC culture, and
this medium could be used for AML cell culture. Our experimental
model thereby represents a highly standardized methodological
approach.
We analyzed our results from the microarray studies by using dif-
ferent bioinformatical strategies. However, independent of the
method used for data analysis we observed that patients were het-
erogeneous with regard to the effects of AML cells on MSCs and usu-
ally differed from normal hematopoietic cells, but a common effect of
the AML cells was a modulation of the TLR–NFκB-chemokine axis in
the normal MSCs. NFκB is also an important regulator of cytokine re-
lease by primary human AML cells (Bruserud et al., 2007). NFκB in-
hibitors are now available and this strategy thus represents a dual
targeting of the cytokine release both in AML cells and MSCs
(Reikvam et al., 2009).
Our coculture experiments demonstrated that all three MSCs
showed a similar low in vitro proliferation; for most patients coculture
of all three MSCs with primary human AML cells did not alter MSC pro-
liferation but aminor increase in the proliferationwas seen for aminor-
ity of patients. No or only minor effects on MSC proliferation were also
seenwhen theywere culturedwith exogenous cytokines or AML super-
natants. These observations suggest that the growth-enhancing effect of
primary AML cells on MSCs depends on the overall intercellular
crosstalk. It should in addition be emphasized that the MSC growthFig. 5.Modulation of the global MSC gene expression proﬁle after coculture with primary huma
GSEA analysis and the balance between inhibitory and stimulatoryNFκB signaling.MSCswere c
from 18 unselected patients. (A, B) The ﬁgure shows the altered expression of genes belonging
NFκB signaling (B). ThemRNA levels are presented as the fold change, i.e. levels for MSCs cocult
shows the median fold change. NFκB signaling is presented as the ratio between stimulatory an
the inhibitory mediator IKBα/βwere determined in cell lysates and the results are presented a
diumalone (horizontal line) togetherwith the results forMSCs coculturedwith leukemic cells de
in cell lysates byduplicate analyses. (B) Theﬁgure shows the altered expression of genes belongi
presented as the fold change, i.e. levels forMSCs coculturedwith AML relative to the correspond
change.enhancementwas observed formost patients despite thewide variation
in cytokine release between patients both in AML cultures and AML–
MSC cocultures.
We compared the cytokine network for MSC cocultures with both
leukemic and normal hematopoietic cells. Because the normal hemato-
poietic cell population of the bone marrow is heterogeneous we then
used a heterogeneous normal population including both immature
cells, more differentiated myeloid cells and a minority of lymphoid
cells. The constitutive mediator release by these normal cells differed
from the AML cells, and their effects on the normal cytokine network
as well as their effects on the MSC gene expression proﬁles differed
from the majority of AML cells. Thus, for most AML patients the
cytokine-mediated crosstalk between MSCs and AML cells results in a
more extensive alteration of MSC gene expression than the normal
bone marrow cells.
The cocultures showed a unique local cytokine network that
reﬂected (i) the high constitutive release of certain mediators by the
MSCs and thereby a relatively small variation between patients of
these cytokines; and (ii) AML-associated differences between patients
that were maintained during coculture even for mediators showing
supra-additive levels. Despite the individual differences the effects of
the cytokine-mediated crosstalk on MSC gene expression signatures
were similar for most patients.
We compared the levels of 24 soluble mediators in culture superna-
tants when MSCs were cultured in AML cocultures and when only AML
culture supernatants were added to MSC cultures. A large number of
soluble mediators then showed higher levels in the cocultures than in
the supernatant cultures. This observation strongly suggests that the ef-
fects of coculture on the local cytokine network are not caused simply
by the presence of AML derived soluble mediators, but that a functional
crosstalk between the cells is required.n AML cells derived from 18 patients; an overview of leading edge genes identiﬁed by the
ultured in transwell cocultures either alone or in the presence of primary AML cells derived
to the GO-term NFκB signaling (A) and the balance between stimulatory versus inhibitory
ured with AML relative to the corresponding levels for MSCs cultured alone, and the ﬁgure
d inhibitory mediators; the levels of the two stimulatory mediators p65/RelA and IKK and
s the ratios p65/IκB and IKK/IκB. The ﬁgure also shows the ratios for MSCs cultured in me-
rived from the18patients. The levels of the three intracellularmediatorswere determined
ng to theGO-terms Toll like receptors (C) and chemokine activity (D). ThemRNA levels are
ing levels forMSCs coculturedwith AML cells, these levels are presented as themedian fold
540 H. Reikvam et al. / Stem Cell Research 15 (2015) 530–541Our microarray studies demonstrated that the cytokine-mediated
crosstalk between MSCs and AML cells altered the global gene expres-
sion proﬁle of the MSCs, and 14 of the 18 patients then showed similar
alterations. These four exceptional patients (i) did not differ from the
other patients with regard to clinical characteristics; (ii) did not have
a common cytokine release proﬁle; (iii) their effects on MSC prolifera-
tion were comparable to the other patients; and (iv) they showed
supra-additive effects on cytokine release similar to the other patients.
Thus, this crosstalk-induced difference in MSC gene expression proﬁle
is not secondary to any of the other clinical/biological differences de-
scribed above.
Coculture ofMSCswith primary AML cells especially altered theMSC
expression of genes involved in TLR-initiated signaling (i.e. genes down-
stream to the receptors), regulation of NFκB and chemokine/interleukin
expression (Fig. 4 and Supplementary Table 3). These three components
form an interacting systemat different levels of the cells (Bruserud et al.,
2007). TLR receptors show transactivation with G-protein coupled re-
ceptors (e.g. chemokine receptors) (Abdulkhalek et al., 2012), NFκB is
an important downstream target of TLR-initiated signaling and NFκB
is in addition an important regulator of chemokine expression/release
in various human cells, including primary AML cells. Therapeutic
targeting of the NFκB system thus seems to represent an opportunity
to modulate the local AML-supporting cytokine network in the bone
marrow through inhibition of cytokine release both by the leukemic
cells and normal stromal cells.
Our Feature Subset Selection Analysis demonstrated that several of
the upregulated genes encoded cytokines that often showed supra-
additive levels in cocultures of MSCs and AML cells, but this was not
true for CCL2 and that were upregulated only at the mRNA but not at
the protein level. One possible explanation is that additional posttran-
scriptionalmechanisms are important for these twomediators, an alter-
native explanation is that these proteins are absorbed/consumed or
degraded during the culture.
Ito et al. (2014) demonstrated that MSCs could support the growth
of AML cells in cocultures, and our present study shows that there is a
bidirectional crosstalk between AML cells and MSCs as the MSC charac-
teristics were altered in our transwell cocultures. However, it is not
known whether the cytokine network alone mediates an AML-
supporting bidirectional crosstalk betweenmesenchymal and leukemic
cells because the study by Ito et al. questioned the importance of the cy-
tokine network and emphasized the importance of direct cell–cell con-
tact for the MSC-associated growth enhancement of the AML cells (Ito
et al., 2014).
To conclude, the cytokine-mediated crosstalk between primary AML
cells and MSCs alters the functional characteristics of the MSCs, and
these effects may thereby contribute to the AML supporting effects of
normal MSCs.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2015.09.008.
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